PTC Therapeutics, Inc. (NASD:PTCT) was a big mover last session, as the company saw its shares a rise a little over 10% on the day. This surge can be attributable to solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock is now up 55.7% in the past one-month time frame.
In the last 30 days, the company did not witness any estimate revisions and the Zacks Consensus Estimate has hit a plateau. However, the recent price action is encouraging, so make sure to keep a close watch on this firm in the near future.
PTC Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked med drug stocks include DepoMed Inc. (NASD:DEPO), Endocyte, Inc. (NASD:ECYT) ) and Lannett Company, Inc. (NYSE:LCI). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
PTC THERAPEUTICS INC (PTCT): Free Stock Analysis Report
LANNETT COMP (LCI): Free Stock Analysis Report
DEPOMED INC (DEPO): Free Stock Analysis Report
ENDOCYTE INC (ECYT): Free Stock Analysis Report
Zacks Investment Research
- Personal Investing Ideas & Strategies
- Finance Trading
- PTC Therapeutics